title: Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.
abstract: Recently, 2 small molecule kinase inhibitors (TKIs), targeting epidermal growth factor receptor (EGFR), have proven effective in the treatment of non-small cell lung cancer. However, it is unknown whether the EGFR double activating mutation of L858R in exon 21 and the in-frame deletion in exon 19 is a predictor of the effectiveness of EGFR-TKIs. We report for the first time a case of non-small cell lung cancer with central nervous system metastases harboring a rare EGFR double activating mutation who showed a good clinical response to erlotinib, regardless of his poor performance status, as swallowing is not possible. Therefore, we suggest that erlotinib may become a therapeutic choice in cases of central nervous system metastases even with poor performance status.
authors.affiliation: Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Masago
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Togashi
authors.forename: Masahide
authors.initials: M
authors.lastname: Fukudo
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Terada
authors.forename: Kaoru
authors.initials: K
authors.lastname: Irisa
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Sakamori
authors.forename: Shiro
authors.initials: S
authors.lastname: Fujita
authors.forename: Young Hak
authors.initials: YH
authors.lastname: Kim
authors.forename: Tadashi
authors.initials: T
authors.lastname: Mio
authors.forename: Ken-Ichi
authors.initials: KI
authors.lastname: Inui
authors.forename: Michiaki
authors.initials: M
authors.lastname: Mishima